Search results
Market Whales and Their Recent Bets on MRNA Options - Moderna (NASDAQ:MRNA)
Benzinga· 5 days agoModerna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with ...
...NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation...
NewMediaWire via Yahoo Finance· 7 days ago10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, ...
COVID summer wave grows, especially in West, with new variant LB.1 on the rise
CBS News· 4 days agoA summertime wave of COVID-19 infections is arriving earlier than last year across a growing share...
‘A head-in-the-sand approach’: The U.S. strategic drug stockpile is inadequate for a bird flu...
Fortune via Yahoo Finance· 16 hours agoThough mRNA vaccines could be made much faster—“in the order of three months” to generate a...
Gateway - Quartz
Quartz· 6 days agoJohnson & Johnson agreed this week to settle a multi-state case alleging it misled consumers about the safety of its talc-based powder products. Moderna said its experimental ...
Nicole Shanahan Lists Reasons She’d Be a Good Prez—And They Make No Sense
The Daily Beast via Yahoo News· 4 days agoJr.’s presidential ticket.Shanahan’s full interview, in which she sat down with Elex Michaelson on...
Gateway - Quartz
Quartz· 6 days agoLike many other wealthy nations, the country bought many more vaccines than it needed—a total of nearly 32 million—to account for potential quality issues, or supply delays ...
Gateway - Quartz
Quartz· 7 days agoHealthcare companies including Ro and Eli Lilly are introducing online supply trackers to help patients navigate ongoing GLP-1 drug shortages. Moderna says it is in talks ...
Gateway - Quartz
Quartz· 6 days agoThe U.S. government is close to finalizing a deal to fund a late-stage trial of Moderna’s mRNA H5N1 bird flu vaccine, as the virus continues to spread rapidly ...
Gateway - Quartz
Quartz· 7 days agoA new study found that Novo Nordisk’s nearly $1,000 per month diabetes medication Ozempic can be produced for less than $5 a month. Novo Nordisk and Johnson & Johnson both announced billion-dollar ...